Document:

EX-10.17

 Exhibit 10.17 

Achillion Pharmaceuticals, Inc. 

Nonstatutory Stock Option Agreement 

Granted Under 2015 Stock Incentive Plan 
  

	1.	Grant of Option. 

 This Nonstatutory Stock Option Agreement (this “Agreement”)
evidences the grant by Achillion Pharmaceuticals, Inc. a Delaware corporation (the “Company”), on [                     ],
20[     ] (the “Grant Date”) to [            ], an [employee][consultant][director] of the Company (the “Participant”), of an option to purchase, in
whole or in part, on the terms provided herein and in the Company’s 2015 Stock Incentive Plan (as amended and/or restated from time to time, the “Plan”), a total of
[             ] shares (the “Shares”) of common stock, $0.001 par value per share, of the Company (“Common Stock”) at $[        ]
per Share. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on [                ] (the “Final Exercise Date”). 

It is intended that the option evidenced by this Agreement shall not be an incentive stock option as defined in Section 422 of the Internal
Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who
acquires the right to exercise this option validly under its terms. 
  

	2.	Vesting Schedule. 

 This option will become exercisable (“vest”) as to
[    ]% of the original number of Shares on the first anniversary of the Grant Date and as to an additional [    ]% of the original number of Shares at the end of each successive [three-month] period following
the [first] anniversary of the Grant Date until the [fourth] anniversary of the Grant Date. 
 The right of exercise shall be cumulative so
that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date
or the termination of this option under Section 3 hereof or the Plan. 
  

	3.	Exercise of Option. 

 (a) Form of Exercise. Each election to exercise this
option shall be in writing in the form of Notice of Stock Option Exercise attached hereto as Exhibit A, signed by the Participant, and received by the Company at its principal office, accompanied by this Agreement, and payment in full in the
manner provided in the Plan. The Participant may purchase less than the number of Shares covered hereby, provided that no partial exercise of this option may be for any fractional share or for fewer than ten whole shares. 

(b) Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be
exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, 

 
officer or director of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants
under the Plan (an “Eligible Participant”). 
 (c) Termination of Relationship with the Company. If the Participant ceases
to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date),
provided that this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final
Exercise Date, violates the non-competition or confidentiality provisions of any employment contract, confidentiality and nondisclosure agreement or other agreement between the Participant and the Company, the right to exercise this option shall
terminate immediately upon written notice to the Participant from the Company describing such violation. 
 (d) Exercise Period Upon
Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such
relationship for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an
authorized transferee), provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall
not be exercisable after the Final Exercise Date. 
 (e) Termination for Cause. If, prior to the Final Exercise Date, the
Participant’s employment or other relationship with the Company is terminated by the Company for Cause (as defined below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment
or other relationship. If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or
other termination is subsequent to the date of the delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed
that the Participant’s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this
option shall, pursuant to the preceding sentence, terminate immediately upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting or severance agreement with the
Company that contains a definition of “cause” for termination of employment or other relationship, “Cause” shall have the meaning ascribed to such term in such agreement. Otherwise, “Cause” shall mean willful misconduct
by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure,
non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The Participant’s employment or other relationship shall be considered to have been
terminated for “Cause” if the Company determines, within 30 days after the Participant’s resignation, that termination for Cause was warranted. 

	4.	Withholding. 

 No Shares will be issued pursuant to the exercise of this option unless
and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option. 

 

	5.	Transfer Restrictions. 

 This option may not be sold, assigned, transferred, pledged or
otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant. 

 

	6.	Provisions of the Plan. 

 This option is subject to the provisions of the Plan (including
the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option. 
 [Remainder of Page
Intentionally Left Blank] 

 IN WITNESS WHEREOF, the Company has caused this option to be executed under its corporate seal by
its duly authorized officer. This option shall take effect as a sealed instrument. 
  

											
		 		 		 	 Achillion Pharmaceuticals, Inc.

					
	 Dated:
	 	 	 		 	By:	 	  

						
		 		 		 		 	      Name:	 	
		 		 		 		 	      Title:	 	

 PARTICIPANT’S ACCEPTANCE 

The Participant hereby accepts the foregoing option and agrees to the terms and conditions thereof. The Participant hereby acknowledges
receipt of a copy of the Plan. 
  

			
	PARTICIPANT:
	
	  

	Name:
		
	Address:	 	  

		
		 	  

		
	Date:	 	  

 Exhibit A 

NOTICE OF STOCK OPTION EXERCISE 

Date:
[                    ] 
 Achillion Pharmaceuticals,
Inc. 
 300 George Street 
 New Haven, CT 06511 

Attention: Treasurer 
 Dear Sir or Madam: 

I am the holder of a Nonstatutory Stock Option granted to me under the Achillion Pharmaceuticals, Inc. (the “Company”) 2015 Stock
Incentive Plan, as amended and/or restated from time to time, on [                     ] for the purchase of
[                 ] shares of Common Stock of the Company at a purchase price of $[        ] per share. 

I hereby exercise my option to purchase [            ] shares of Common Stock (the
“Shares”), for which I have enclosed [            ] in the amount of [            ]. Please register my stock
certificate as follows: 

Name(s):                      
                                     

 
  

Address:                      
                                     

Tax
I.D.#:                                        
                 
 I represent, warrant and covenant as
follows: 
 1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of
the Shares in violation of the Securities Act of 1933, as amended (the “Securities Act”), or any rule or regulation under the Securities Act. 

2. I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to
evaluate the merits and risks of my investment in the Company. 
 3. I have sufficient experience in business, financial and investment matters to be able
to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase. 
 4. I can afford a
complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period. 

 Exhibit A 

 

	
	 Very truly yours,

	
	 
	 (Signature)

Name:EX-10.23

 Exhibit 10.23 

ACHILLION 
 EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”), effective as of January 2, 2016 (the “Effective Date”), is entered into by
Achillion Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 300 George Street, New Haven, CT 06511-6624 (the “Company”), and Joel Barrish, Ph.D. (the “Executive”). 

WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company pursuant to the terms and
conditions set forth in this Agreement. 
 NOW, THEREFORE, in consideration ofthe employment of the Executive, and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive agree as follows: 
 1.
Term of Employment. The Company hereby agrees to employ the Executive, and the Executive hereby accepts employment with the Company, upon the terms set forth in this Agreement, for the period commencing on the Effective Date and ending on December
31, 2016, unless earlier terminated pursuant to the provisions of Section 4 or extended pursuant to the provisions herein (such period, the “Employment Period”). On January 1, 2017, and on each yearly anniversary of such date thereafter,
this Agreement shall automatically renew for successive one-year periods unless, at least 6 months prior to the applicable expiration date, either party has notified the other party that the Agreement shall not so renew. 

2. Title; Capacity. During the Employment Period, the Executive shall serve as Executive Vice President and Chief Scientific Officer or in
such other reasonably comparable position as the Board of Directors of the Company (the “Board”) may determine from time to time. The Executive shall be based at the Company’s headquarters in New Haven, Connecticut, or such place or
places in the continental United States as the Board shall determine. The Executive shall be subject to the supervision of, and shall have such authority as is delegated to the Executive by the Company’s ChiefExecutive Officer (“CEO”)
and the Board. 
 The Executive hereby accepts such employment and agrees to undertake the duties and responsibilities inherent in such
position and such other duties and responsibilities as the CEO or the Board shall from time to time reasonably assign to the Executive. The Executive agrees to devote his entire business time, attention and energies to the business and interests of
the Company during the Employment Period. The Executive agrees to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein which may be adopted from time to time by the Company. The
Executive will be eligible to participate in the Company’s performance review process. 

 3. Compensation and Benefits. 

3.1 - The Company shall pay the Executive, in periodic installments in accordance with the Company’s customary payroll practices, a base
salary at the biweekly rate of $16,923.08 (which if annualized equals $440,000) (the “Base Salary”), commencing on the Effective Date. Such Base Salary shall be subject to increase thereafter as determined by the Board. 

3.2 Annual Bonus. Following the end of each fiscal year and subject to the approval of the Board, the Executive shall be eligible to
receive a discretionary retention and performance bonus (the “Annual Bonus”). The target amount of such Annual Bonus will be 35% of the Executive’s then current Base Salary (the “Target Bonus”), based on the Company’s
performance and the Executive’s individual performance during the applicable fiscal year, as determined by the Board in its sole discretion. The Executive must be an active employee of the Company on the date any Annual Bonus is distributed in
order to be eligible for and to earn any bonus award, as it also serves as an incentive to remain employed by the Company. 
 3.3 Equity
Award. Subject to approval by the Company’s Compensation Committee, on or about the Effective Date, the Executive shall be granted, pursuant to the Company’s 2015 Stock Incentive Plan (the “Plan”), an option to purchase
250,000 shares of Common Stock, $0.001 par value (“Common Stock”) of the Company pursuant to the terms and conditions of the Plan and a stock option agreement issued thereunder, such option to (a) have an exercise price per share equal to
the closing price of the Company’s Common Stock on the NASDAQ Global Select Market on the date of grant, and (b) vest and become exercisable, subject to the Employee’s continued service, at a rate of25% of the total shares underlying the
option on the first anniversary of the date of grant and as to an additional6.25% of the total shares underlying the grant at the end of each full calendar quarter thereafter, subject to continued service. The Executive may be eligible to receive
additional stock options or stock based awards pursuant to the Plan (or a successor stock incentive plan) from time to time, provided that any such stock options or stock based awards will be made, if at all, solely at the discretion of the Board
and upon such terms and conditions as the Board shall determine. 
 3.4 Sign-On Bonus. The Executive will receive a one-time cash
“sign-on” bonus of $200,000 (the “Sign-on Bonus”), payable no later than the second payroll period after the Effective Date. If, prior to the one-year anniversary of the Effective Date, the Executive’s employment is
terminated for Cause (as defined below) or the Executive resigns without Good Reason (as defined below), the Executive shall be required to repay the Sign-on Bonus. If, following the one-year anniversary of the Effective Date but prior to the
two-year anniversary of the Effective Date, the Executive’s employment is terminated for Cause or the Executive resigns without Good Reason, the Executive shall be required to repay 50% of the Sign-on Bonus. Any such repayment must be made
within 10 days following the Executive’s separation from employment. By countersigning this Agreement, the Executive hereby agrees to make such repayment. 

3.5 Fringe Benefits. The Executive shall be entitled to participate in all benefit programs that the Company establishes and makes
available to its Executives, if any, to the extent that the Executive is eligible under the plan documents governing those programs. 

 
Benefits are subject to change at any time in the Company’s sole discretion. The Executive shall be entitled to up to 20 days of paid time off per calendar year in accordance with the
Company’s policy. 
 3.6 Reimbursement of Expenses. The Company shall reimburse the Executive for all reasonable travel,
entertainment and other expenses incurred or paid by the Executive in connection with, or related to, the performance of his duties and responsibilities under this Agreement (other than expenses arising out of or related to commuting costs,
including temporary housing and meal expenses), in accordance with the policies and procedures, and subject to the limitations, adopted by the Company from time to time. 

3.7 Commuting Assistance. The Company agrees to pay the Executive $20,000 each year in which he commutes between Pennsylvania and
Connecticut (the “Commuting Compensation”). The Commuting Compensation shall be paid in two equal installments (one in January and one in July), for the purpose of covering expenses incurred by the Executive in commuting between
Pennsylvania and Connecticut, including travel expenses, temporary housing expenses near the Company’s Connecticut office, and meal expenses. The Company also will pay to the Executive an additional amount, determined by the Company in its sole
discretion, as an approximate gross-up of the Commuting Compensation; provided, however, that any such gross-up payment shall be made by no later than the end of the calendar year next following the calendar year in which the Executive remits such
taxes. 
 3.8 Withholdings. All compensation payable to the Executive shall be subject to applicable taxes and withholdings 

4. Termination of Employment Period. This Agreement and the employment of the Executive shall terminate upon the occurrence of any of
the following: 
 4.1 Expiration of the Employment Period by notice of non-renewal in accordance with Section 1; 

4.2 At the election of the Company for Cause, immediately upon written notice by the Company to the Executive, which notice shall identify the
Cause upon which the termination is based; 
 4.3 At the election of the Executive for Good Reason (as defined below), pursuant to the
provisions set forth below; 
 4.4 Upon the death or Disability (as defined below) of the Executive; 

4.5 At the election of the Company without Cause, upon not less than fifteen (15) days’ prior written notice of termination; or 

4.6 At the election of the Executive without Good Reason, upon not less than fifteen (15) days’ prior written notice of termination. 

 5. Effect of Termination. 

5.1 Termination by the Company Without Cause or by the Executive for Good Reason Within 12 Months Following a Change in Control.
If, within 12 months following a Change in Control Date, the Executive’s employment is terminated by the Company without Cause (other than due to his Disability or death) or the Executive resigns for Good Reason, then, subject to the conditions
of Section 7 and in accordance with the timing and payment terms set forth in Section 7: 
 (a) the Company shall, for a period of 12 months
following the Executive’s date of termination (the “Date of Termination”), continue to pay to the Executive, in accordance with the Company’s customary payroll practices, his then current Base Salary as severance; 

(b) if the Executive is eligible for and timely elects to continue receiving group medical and/or dental insurance under the continuation
coverage rules known as COBRA, the Company will continue to pay the share of the premium for such coverage that it pays for active and similarly-situated employees who receive the same type of coverage (single, family, or other) until the earlier of
(x) the end of the 12th month after the Date of Termination, and (y) the date the covered individual’s COBRA continuation coverage expires, unless, as a result of a change in legal requirements, the Company’s provision of payments for
COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply; and 
 (c) the Executive
will receive the Target Bonus for the year in which his Date of Termination occurs. 
 5.2 Termination by the Company Without Cause or by
the Executive for Good Reason Prior to, or More than 12 Months Following, a Change in Control. If, prior to a Change in Control Date or more than 12 months following a Change in Control Date, the Executive’s employment is terminated
by the Company without Cause (other than for Disability or death) or the Executive resigns for Good Reason, then, subject to the conditions of Section 7 and in accordance with the payment terms set forth in Section 7: 

(a) the Company shall, until the earlier of (x) the date that is twelve (12) months after the Date of Termination, and (y) the date upon which
the Executive commences full-time employment with another company, continue to pay to the Executive, in accordance with the Company’s customary payroll practices, his then current Base Salary as severance (and the Executive shall be required to
immediately inform the Company upon his commencement of full-time employment with another company); 
 (b) if the Executive is eligible for
and timely elects to continue receiving group medical and/or dental insurance under the continuation coverage rules known as COBRA, the Company will continue to pay the share of the premium for such coverage that it pays for active and
similarly-situated employees who receive the same type of coverage (single, family, or other) until the earlier of (x) the end of the 12th month after the Date of Termination, and (y) the date the covered individual’s COBRA continuation
coverage expires, unless, as a result of a change in legal requirements, the Company’s provision of payments for COBRA will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply; and 

 (c) the Executive will receive a pro-rated bonus payment equal to (x) the Annual Bonus, if any,
paid to the Executive for the most recent fiscal year ending prior to the Date of Termination (or to be paid to the Executive for such fiscal year if not yet paid), multiplied by (y) a fraction, the numerator of which is the number of days the
Executive was employed by the Company in the then current fiscal year prior to the Date of Termination and the denominator of which is 365. 

5.3 Termination by the Company for Cause, by the Executive Without Good Reason, or Due to Death or Disability, or Due to Expiration
of the Employment Period by Notice of Non-Renewal. If the Company terminates the Executive’s employment for Cause or the Executive resigns without Good Reason, or the Executive’s employment terminates due to his death or
Disability, or the Employment Period expires by notice of non-renewal, then the Company’s obligations under this Agreement shall immediately cease and the Executive shall be entitled to only the Base Salary that has accrued and to which the
Executive is entitled as of the Date of Termination. The Executive shall not be entitled to any other compensation or consideration, including any Annual Bonus not yet paid, that the Executive may have received had the Employment Period not ended.

 6. Equity Acceleration Benefits to Executive. 

6.1 Equity Acceleration in Connection with Change in Control. If a Change in Control Date occurs during the Employment Period, then,
effective upon the Change in Control Date, (a) the vesting schedule of each outstanding option to purchase shares of Common Stock of the Company held by the Executive shall be accelerated in part so that the option shall become exercisable for an
additional number of shares equal to 50% of the original number of shares of Common Stock subject to the option immediately prior to such Change in Control; the remaining unvested shares shall continue to become vested in accordance with the
original vesting schedule set forth in the applicable option agreement; and (b) unvested shares, or units, if any, with respect to each restricted stock or stock unit award held by the Executive immediately following the Change in Control shall be
vested such that the number of unvested shares or units shall be reduced by 50% of the original number of shares or units subject to such restricted stock or stock unit award; the remaining unvested shares or units shall continue to vest in
accordance with the original schedule set forth in the applicable restricted stock or stock unit award agreement; provided that the vesting will not accelerate the distribution of shares underlying equity awards if such acceleration of distribution
would trigger taxation under Section 409A(a)(l)(B) of the Internal Revenue Code of 1986 and the guidance issued thereunder (“Section 409A” of the “Code”). 

6.2 Equity Acceleration in Connection with Termination Without Cause or For Good Reason Within 12 Months Following a Change in
Control. If, within 12 months following a Change in Control Date, the Executive’s employment with the Company is terminated by the Company without Cause (other than due to Disability or death) or the Executive resigns for Good Reason, then
(a) each outstanding option to purchase shares of Common Stock of the Company held by the Executive shall become immediately exercisable in full; and (b) each restricted stock or stock unit award held by the Executive shall be deemed to be fully
vested and free from forfeiture, and, to the extent applicable, will no longer be subject to a right of repurchase by or forfeiture to the Company; provided that the vesting will not accelerate the distribution of shares underlying equity awards if
such acceleration of distribution would trigger taxation under Section 409A of the Code. 

 6.3 Equity Acceleration in Connection with Termination Without Cause or For Good Reason
Prior to, or More than 12 Months Following, a Change in Control. If, prior to a Change in Control Date or more than 12 months following a Change in Control Date, the Executive’s employment with the Company is terminated by the Company
without Cause (other than due to Disability or death) or the Executive resigns for Good Reason, then (a) the vesting schedule of each outstanding option to purchase shares of Common Stock of the Company held by the Executive shall be accelerated in
part so that the option shall become exercisable for an additional number of shares equal to 25% of the original number of shares of Common Stock subject to the option immediately prior to such date of termination and (b) unvested shares, or units,
if any, with respect to each restricted stock or stock unit award held by the Executive as of the date of such termination shall be vested such that the number of unvested shares or units shall be reduced by 25% of the original number of shares or
units subject to such restricted stock or stock unit award; provided that the vesting will not accelerate the distribution of shares underlying equity awards if such acceleration of distribution would trigger taxation under Section 409A of the Code.

 7. Release. The obligation of the Company to make the payments and provide the benefits to the Executive under Section 5.1 or 5.2 is
conditioned upon the Executive signing and delivering to the Company a severance and release of claims agreement in a form to be provided by the Company (which will include, at a minimum, a release of all releasable claims and non-disparagement and cooperation obligations) (the “Executive Release”), which Executive Release must become irrevocable within sixty (60) days following the Date of Termination (or such shorter period as
the Company may provide, which shall not be less than 30 days following the Date of Termination). The Company shall commence or make, as applicable, the payments under Section 5.1 or 5.2 on the first payroll period following the date the Executive
Release becomes irrevocable; provided, however, that if the 60th day following the Date of Termination falls in the calendar year following the year of the Executive’s termination of employment, the payments will not commence or be made, as
applicable, earlier than the first payroll period of such later calendar year; and provided further that the payment of any amounts pursuant to Section 5.1 or 5.2 shall be subject to the terms and conditions set forth in Section 9.2. 

8. Termination Obligations. 

8.1 Return of Company’s Property. The Executive hereby acknowledges and agrees that all personal property, including, without
limitation, all books, manuals, records, reports, notes, contracts, lists, blueprints and other documents or materials, or copies thereof, and equipment furnished to or prepared by the Executive in the course of or incident to the Executive’s
employment, belong to the Company and shall be promptly returned to the Company upon termination of Executive’s employment or earlier request by the Company. Following termination, the Executive will not retain any written or other tangible
material containing any proprietary information or confidential information of the Company. 
 8.2 Cooperation in Pending Work.
Following any termination of the Executive’s employment, the Executive shall fully cooperate with the Company in all matters 

 
relating to the winding up of pending work on behalf of the Company and the orderly transfer of work to other executives of the Company. The Executive shall also cooperate in the defense of any
action brought by any third party against the Company that relates in any way to the Executive’s acts or omissions while employed by the Company. 

9. Taxes. 
 9.1 280G. 

(a) Notwithstanding any other provision of this Agreement, except as set forth in Section 9.1(b), in the event that the Company undergoes a
“Change in Ownership or Control” (as defined below), the Company shall not be obligated to provide to the Executive a portion of any “Contingent Compensation Payments” (as defined below) that the Executive would otherwise be
entitled to receive to the extent necessary to eliminate any “excess parachute payments” (as defined in Code Section 280G(b)(l)) for the Executive. For purposes of this Section 9.1, the Contingent Compensation Payments so eliminated shall
be referred to as the “Eliminated Payments” and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be
referred to as the “Eliminated Amount.” 
 (b) Notwithstanding the provisions of 9.1(a), no such reduction in Contingent
Compensation Payments shall be made if (i) the Eliminated Amount (computed without regard to this sentence) exceeds (ii) 110% of the aggregate present value (determined in accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or
any successor provisions) of the amount of any additional taxes that would be incurred by the Executive if the Eliminated Payments (determined without regard to this sentence) were paid to him or her (including, state and federal income taxes on the
Eliminated Payments, the excise tax imposed by Section 4999 of the Code payable with respect to all of the Contingent Compensation Payments in excess of the Executive’s “base amount” (as defined in Section 280G(b)(3) of the Code), and
any withholding taxes). The override of such reduction in Contingent Compensation Payments pursuant to this Section 9.1(b) shall be referred to as a “Section 9.1(b) Override.” For purpose ofthis paragraph, if any federal or state income
taxes would be attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax rate provided by law. 

(c) For purposes of this Section 9.1 the following terms shall have the following respective meanings: 

(i) “Change in Ownership or Control” shall mean a change in the ownership or effective control of the Company or in the ownership of
a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code. 
 (ii) “Contingent
Compensation Payment” shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Agreement or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and
that is contingent (within the meaning of Section 280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the Company. 

 (d) Any payments or other benefits otherwise due to the Executive following a Change in Ownership
or Control that could reasonably be characterized (as determined by the Company) as Contingent Compensation Payments (the “Potential Payments”) shall not be made until the dates provided for in this Section 9.l(d). Within 30 days after
each date on which the Executive first becomes entitled to receive (whether or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify the Executive (with reasonable
detail regarding the basis for its determinations) (i) which Potential Payments constitute Contingent Compensation Payments, (ii) the Eliminated Amount and (iii) whether the Section 9.1(b) Override is applicable. Within 30 days after delivery of
such notice to the Executive, the Executive shall deliver a response to the Company (the “Executive Response”) stating either (A) that he or she agrees with the Company’s determination pursuant to the preceding sentence, or (B) that
he or she disagrees with such determination, in which case he or she shall set forth (i) which Potential Payments should be characterized as Contingent Compensation Payments, (ii) the Eliminated Amount, and (iii) whether the Section 9.l(b) Override
is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company’s initial determination shall be final. If and to the extent that any Contingent Compensation Payments are
required to be treated as Eliminated Payments pursuant to this Section 9.1, then the payments shall be reduced or eliminated, as determined by the Company, in the following order: (i) any cash payments, (ii) any taxable benefits, (iii) any
nontaxable benefits, and (iv) any vesting of equity awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that triggers the applicability of the excise tax, to the extent
necessary to maximize the Eliminated Payments. If the Executive states in the Executive Response that he or she agrees with the Company’s determination, the Company shall make the Potential Payments to the Executive within three business days
following delivery to the Company of the Executive Response (except for any Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). lfthe Executive states in
the Executive Response that he disagrees with the Company’s determination, then, for a period of 60 days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve such dispute. If such
dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration in the State of Connecticut, in accordance with the rules of the American Arbitration Association then in effect. Judgment may be entered on
the arbitrator’s award in any court having jurisdiction. The Company shall, within three business days following delivery to the Company of the Executive Response, make to the Executive those Potential Payments as to which there is no dispute
between the Company and the Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due). The
balance of the Potential Payments shall be made within three business days following the resolution of such dispute. Subject to the limitations contained in Sections 9.1(a) and (b) hereof, the amount of any payments to be made to the Executive
following the resolution of such dispute shall be increased by amount of the accrued interest thereon computed at the prime rate announced from time to time by The Wall Street Journal, compounded monthly from the date that such payments originally
were due. 

 (e) The provisions of this Section 9.1 are intended to apply to any and all payments or benefits
available to the Executive under this Agreement or any other agreement or plan of the Company under which the Executive receives Contingent Compensation Payments. 

9.2 Payment Subject to 409A. Subject to this Section 9, any severance payments or benefits under this Agreement shall begin only upon
the date of the Executive’s “separation from service” (determined as set forth below) which occurs on or after the date of the Executive’s termination of employment. The following rules shall apply with respect to distribution of
the payments and benefits, if any, to be provided to the Executive under this Agreement: 
 (a) It is intended that each installment of the
severance payments and benefits provided under this Agreement shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor the Executive shall have the right to accelerate or defer the delivery of any such
payments or benefits except to the extent specifically permitted or required by Section 409A. 
 (b) If, as of the date of the
Executive’s “separation from service” from the Company, the Executive is not a “specified Executive” (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the
dates and terms set forth in this Agreement. 
 (c) If, as of the date of the Executive’s “separation from service” from the
Company, the Executive is a “specified Executive” (within the meaning of Section 409A), then: 
 (i) Each installment of the
severance payments and benefits due under this Agreement that will be paid within the short-term deferral period (as defined in Section 409A) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4)
to the maximum extent permissible under Section 409A; and (ii) each installment of the severance payments and benefits due under this Agreement that is not described in Section 9.2(c)(i) above and that would, absent this subsection, be paid within
the six-month period following the Executive’s “separation from service” from the Company shall be paid during the ten day period following the date that is six months and one day after such separation from service (or, if earlier,
the Executive’s death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following the Executive’s separation from
service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and
benefits if and to the maximum extent that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to
separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of the second taxable year following the
taxable year in which the separation from service occurs. 

 (d) The determination of whether and when the Executive’s separation from service from the
Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Section 9.2, “Company” shall include all persons with
whom the Company would be considered a single employer as determined under Treasury Regulation Section 1.409A-1(h)(3). 
 (e) All
reimbursements and in-kind benefits provided under this Agreement shall be made or provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where
applicable, the requirements that (i) any reimbursement is for expenses incurred during the Executive’s lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a
calendar year may not affect the expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is
incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit. 
 (f) Executive
expressly acknowledges and agrees that the Company is not making any representations or warranties to him or her and shall have no liability to him/her or any other person with respect to payments made under this Agreement if any provisions of or
payments under the Agreement are determined to constitute deferred compensation subject to Code Section 409A but not to satisfy the conditions of that section. 

10. Restrictive Covenant Agreement. As a condition of his employment, the Executive shall execute both the Nondisclosure and Assignment
of Inventions Agreement and the Non-Competition Agreement provided to him contemporaneously with this Agreement. 
 11. Absence of
Restrictions. The Executive represents and warrants that he is not bound by any employment contracts, restrictive covenants or other restrictions that prevent him from entering into employment with, or carrying out his responsibilities for, the
Company, or which are in any way inconsistent with any of the terms of this Agreement. 
 12. Definitions. For purposes of this Agreement,
the following terms shall have the following meanings: 
 12.1 “Cause” shall mean (a) a good faith finding by the Company that (i)
the Executive has failed to substantially perform his or her reasonably assigned duties for the Company, or (ii) the Executive has engaged in dishonesty, gross negligence or misconduct, which dishonesty, gross negligence or misconduct has had a
material adverse effect on the Company, (b) the conviction of the Executive of, or the entry of a plea of guilty or nolo contendere by the Executive to, any felony, (c) breach by the Executive of any material provision of this Agreement or other
agreement with the Company (which breach is not cured within 30 days following written notice by the Company thereof), or (d) breach by the Executive of the Nondisclosure and Assignment of lnventions Agreement and/or the Non-Competition Agreement.

 12.2 “Change in Control” shall mean the sale of all or substantially all of the capital
stock (other than the sale of capital stock to one or more venture capitalists or other institutional investors pursuant to an equity financing (including a debt financing that is convertible into equity) of the Company approved by a majority of the
Board), assets or business of the Company, by merger, consolidation, sale of assets or otherwise (other than a merger or consolidation in which all or substantially all of the individuals and entities who were beneficial owners of the Common Stock
immediately prior to such transaction beneficially own, directly or indirectly, more than 50% of the outstanding securities entitled to vote generally in the election of directors of the resulting, surviving or acquiring corporation in such
transaction), provided that, where applied to compensation subject to Section 409A, any acceleration of or change in payment shall only apply (if required by Section 409A) if the corporate transaction is also a change in control event described in
Treasury Regulation 1.409A-3(i)(5). 
 12.3 “Change in Control Date” means the first date during the Employment Period on which a
Change in Control occurs. Anything in this Agreement to the contrary notwithstanding, if(a) a Change in Control occurs, (b) the Executive’s employment with the Company is terminated without Cause (other than due to the Executive’s death or
Disability) within 60 days prior to the date on which the Change in Control occurs, and (c) it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a third party who has taken steps reasonably
calculated to effect a Change in Control or (ii) otherwise arose in connection with or in anticipation of a Change in Control, then the “Change in Control Date” shall mean the date immediately prior to the date of such termination of
employment. Where applicable, the Company shall take such steps as are reasonably practicable as of the termination date to preserve the availability of equity compensation that may expire (other than by reaching the full term of an option) during
the 60 day period (by vesting and freezing the equity) pending the occurrence of the Change in Control. 
 12.4 “Disability” shall
mean the inability of the Executive, due to a physical or mental disability, for a period of 90 days, whether or not consecutive, during any 360-day period to perform the services contemplated under this Agreement, with or without reasonable
accommodation, as that term is defined under state or federal law. A determination of disability shall be made by a physician satisfactory to both the Executive and the Company, provided that if the Executive and the Company do not agree on a
physician, the Executive and the Company shall each select a physician and these two together shall select a third physician, whose determination as to disability shall be binding on all parties. 

12.5 “Good Reason” shall mean the occurrence, without the Executive’s prior written consent, of any of the following events:
(i) a material diminution of the Executive’s base compensation; (ii) a requirement that the Executive’s principal place of providing services to the Company change by more than 30 miles, other than in a direction that reduces the
Executive’s daily commuting distance; (iii) any material breach by the Company or any successor thereto of a material provision of this Agreement; or (iv) a material diminution in the Executive’s authority, duties, or responsibilities,
provided, however, and for the avoidance of doubt, that Good Reason shall not exist if the Executive no longer holds the same title or functional role within an entity resulting from a Change in Control, so long as the Executive’s
responsibilities are not substantially diminished. Notwithstanding the occurrence of any of the foregoing events or circumstances, a resignation shall not be deemed to constitute resignation for Good Reason

 
unless (x) the Executive gives the Company a written notice of the purported Good Reason (no more than 90 days after the initial existence of such event or circumstance), (y) such event or
circumstance has not been fully corrected (and the Executive has not been reasonably compensated for any losses or damages resulting therefrom) within 30 days following the Company’s receipt of such notice, and (z) if the Company does not
correct, the Executive ends his employment not more than 30 days following the period to correct in (y). 
 13. Miscellaneous. 

13.1 Entire Agreement; Modification. This Agreement constitutes the entire understanding and agreement between the parties hereto with
regard to the subject matter hereof, superseding all prior understandings and agreements, whether written or oral. The Executive is not relying on any representations other than those set forth in this Agreement. 

13.2 Notices. Any notice delivered under this Agreement shall be deemed du1y delivered three business days after it is sent by registered or
certified mail, return receipt requested, postage prepaid, or one business day after it is sent for next-business day delivery via a reputable nationwide overnight courier service, to the Company at its principal headquarters and to the Executive at
the address most recently shown on the personnel records of the Company. Either party may change the address to which notices are to be delivered by giving notice of such change to the other party in the manner set forth in this Section 13.2. 

13.3 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa. 
 13.4 Amendment.
This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive and approved by a majority of the members of the Board. 

13.5 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Connecticut (without
reference to the conflicts of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court of the State of Connecticut (or, if appropriate, a
federal court located within Connecticut), and the Company and the Executive each consents to the jurisdiction of such a court. The Company and the Executive each hereby irrevocably waives any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement. 
 13.6 Successors and Assigns. This Agreement shall
be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company’s assets or business,
provided, however, that the obligations of the Executive are personal and shall not be assigned by him. 
 13.7 Waivers. No delay or
omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be
construed as a bar to or waiver of any right on any other occasion. 

 13.8 Captions. The captions of the sections of this Agreement are for convenience of
reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. 
 13.9 Severability.
In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

13.10 Executive’s Acknowledgments. The Executive acknowledges that he: (i) has read this Agreement; (ii) has been represented in the
preparation, negotiation, and execution of this Agreement by legal counsel of the Executive’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is fully aware of
the legal and binding effect of this Agreement; and (v) understands that the law firm of Wilmer Cutler Pickering Hale and Dorr LLP is acting as counsel to the Company in connection with the transactions contemplated by the Agreement, and is not
acting as counsel for the Executive. 
 14. Indemnification 

14.1 Company shall defend, indemnify, and hold Executive harmless from and against any and all third party claims, actions,
suits, and proceedings which may at any time be brought against Executive, as well as from and against all related liabilities, damages, judgments, settlements, fines, penalties, costs or expenses (including but not limited to reasonable
attorney’s fees and costs or expenses of investigating or defending any actions or threatened actions) suffered or incurred by Executive arising out of or relating to any claim that Executive has violated or breached the applicable non-competition provisions of his Bristol-Myers Squibb Company Market Share Units Agreement or Performance Share Units Agreement by becoming an employee of Company. Executive shall inform the Company’s Chief
Executive Officer and General Counsel promptly of any potential conflicts or issues that trigger or could potentially trigger a conflict with Executive’s contractual obligations. 

[Remainder of page is intentionally left blank] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year set
forth above. 
  

	
	ACHILLION PHARMACEUTICALS, INC.
	
	By:
	
	         /s/ Milind Deshpande

	          Name: Milind S. Deshpande
	          Title: Chief Executive Officer
	
	EXECUTIVE:
	
	         /s/ Joel Barrish

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]